Squamous cell cancer (SCC) is a type of skin cancer ... This does not mean SCC is not dangerous, though. The more advanced SCC becomes before doctors diagnose it, the more opportunity it has ...
Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.
Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...
A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.
An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...
On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve survival compared with placebo in patients with locally advanced squamous cell ...
In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...
HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...
The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback